EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism

Luisa Weiss iD, Wido Uhrig, Sarah Kelliher, Paulina B Szklanna, Tadhg Prendiville, Shane P Comer, Osasere Edebiri, Karl Egan, Áine Lennon, Barry Kevane, Sean Murphy, Fionnuala Ní Áinle und 1 weitere

PROTEOMICS – Clinical Applications · 2024

DOI: 10.1002/prca.202300014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2024. Verfasst von Luisa Weiss und 12 weiteren Autor:innen. Beteiligte Einrichtung: UCD Conway SPHERE Research group, Conway Institute, University College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Rivaroxaban, Venous Thromboembolism, Extracellular Vesicles, Proteomics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality worldwide. Rivaroxaban, a direct oral factor Xa inhibitor, mediates anti‐inflammatory and cardiovascular‐protective effects besides its well‐established anticoagulant properties; yet, these remain poorly characterized. Extracellular vesicles (EVs) are considered proinflammatory messengers regulating a myriad of (patho)physiological processes and may be highly relevant to the pathophysiology of VTE. The effects of Rivaroxaban on circulating EVs in VTE patients remain unknown. We have established that differential EV biosignatures are found in patients with non‐valvular atrial fibrillation anticoagulated with Rivaroxaban versus warfarin. Here, we investigated whether differential proteomic profiles of circulating EVs could also be found in patients with VTE. Methods and Results We performed comparative label‐free quantitative proteomic profiling of enriched plasma EVs from VTE patients anticoagulated with either Rivaroxaban or warfarin using a tandem mass spectrometry approach. Of the 182 quantified proteins, six were found to be either exclusive to, or enriched in, Rivaroxaban‐treated patients. Intriguingly, these proteins are involved in negative feedback regulation of inflammatory and coagulation pathways, suggesting that EV proteomic signatures may reflect both Rivaroxaban's anti‐coagulatory and anti‐inflammatory potential.

Conclusions

These differences suggest Rivaroxaban may have pleiotropic effects, supporting the reports of its emerging anti‐inflammatory and cardiovascular‐protective characteristics relative to warfarin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanVenous ThromboembolismExtracellular VesiclesProteomicsHumansMaleFemaleMiddle AgedFactor Xa InhibitorsCardiotonic AgentsAged

Stichwörter der Autor:innen

anticoagulationextracellular vesiclesinflammationrivaroxabanvenous thromboembolism

Substanzen

RivaroxabanFactor Xa InhibitorsCardiotonic Agents

Autor:innen und Institutionen

  • UCD Conway SPHERE Research group, Conway Institute, University College Dublin, Dublin, Ireland.
  • School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.
  • Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland.
  • Department of Stroke Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
  • School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

ORCID-Profile: Luisa Weiss, Patricia B Maguire

Förderung

  • Bayer

Zitieren

APA

Weiss, L., Uhrig, W., Kelliher, S., Szklanna, P. B., Prendiville, T., Comer, S. P., Edebiri, O., Egan, K., Lennon, Á., Kevane, B., Murphy, S., Ní Áinle, F., & Maguire, P. B. (2024). Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.202300014

Vancouver

Weiss L, Uhrig W, Kelliher S, Szklanna PB, Prendiville T, Comer SP, et al. Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism. PROTEOMICS – Clinical Applications. 2024. doi:10.1002/prca.202300014

BibTeX
@article{Weiss2024,
  author = {Weiss, Luisa and Uhrig, Wido and Kelliher, Sarah and Szklanna, Paulina B and Prendiville, Tadhg and Comer, Shane P and Edebiri, Osasere and Egan, Karl and Lennon, Áine and Kevane, Barry and Murphy, Sean and Ní Áinle, Fionnuala and Maguire, Patricia B},
  title = {Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2024},
  doi = {10.1002/prca.202300014}
}
Kostenlos starten →